In addition to second-site mutations at the dimer interface, the authors identified resistant mutations in IDH that interfere with NADPH binding and confirmed their presence in cases of IDH2R140Q mutant AML patients that developed resistance to Enasidenib [102]. Here, IDH2 is linked to acute myeloid leukemia.